Select Language
IL-5
IL-5 Overview
| English Name | Interleukin-5 | Approved Drugs | 3 |
| Drugs in Clinical Trials | 6 | Target Synonym | T-cell replacing factor，IL5，Interleukin 5，Eosinophil Differentiation Factor，Colony-Stimulating Factor， Eosinophil，B-Cell Differentiation Factor I，Interleukin-5，IL-5，TRF，Interleukin 5 (Colony-Stimulating Factor， Eosinophil)，B Cell Differentiation Factor I，EDF |
| Highest Development Stage | Approved | ||
| English Name | Interleukin-5 |
| Target Synonym | T-cell replacing factor，IL5，Interleukin 5，Eosinophil Differentiation Factor，Colony-Stimulating Factor， Eosinophil，B-Cell Differentiation Factor I，Interleukin-5，IL-5，TRF，Interleukin 5 (Colony-Stimulating Factor， Eosinophil)，B Cell Differentiation Factor I，EDF |
| Approved Drugs | 3 |
| Drugs in Clinical Trials | 6 |
| Highest Development Stage | Approved |
IL-5 Product List
- Product Category
Protein (8)Kits (2)
- Product Status
Launched (10)
- Species
Human (5)Rabbit (1)Mouse (1)Cynomolgus (1)Canine (1)Rat (1)
- Tag
His Tag (6)His Tag & Avi Tag (1)- (2)Tag Free (1)
- Conjugate
Unconjugated (7)Biotin-labeled (1)- (2)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
HOT IL5-H52H3 |  Human | HEK293 | Human IL-5 Protein, His Tag |  |  |  |  Add to Cart |
HOT IL5-H82Q5 | Human | HEK293 | Biotinylated Human IL-5 Protein, His,Avitag™ (MALS verified) |  | | | Add to Cart |
HOT IL5-C52H3 |  Cynomolgus | HEK293 | Cynomolgus IL-5 Protein, His Tag, low endotoxin |  | | | Add to Cart |
HOT IL5-R52H4 |  Rabbit | HEK293 | Rabbit IL-5 Protein, His Tag |  | | | Add to Cart |
CEA-C011 | Human | - | Human IL-5 ELISA Kit | Add to Cart | |||
EP-128 | Human | - | IL-5 [Biotinylated] : IL-5Rα Inhibitor Screening ELISA Kit | Add to Cart | |||
IL5-H5214 | Human | HEK293 | Human IL-5 Protein, premium grade |  | |  | Add to Cart |
IL5-M52H3 |  Mouse | HEK293 | Mouse IL-5 Protein, His Tag (MALS verified) |  | | | Add to Cart |
IL5-C5243 |  Canine | HEK293 | Canine IL-5 Protein, His Tag (MALS verified) |  | | | Add to Cart |
IL5-R5243 |  Rat | HEK293 | Rat IL-5 Protein, His Tag (MALS verified) |  | | | Add to Cart |
Total: 10
- 1
IL-5 Background
Interleukin 5 (IL5) is an interleukin produced by type-2 T helper cells and mast cells. IL-5 is a 115-amino acid (in human, 133 in the mouse) -long TH2 cytokine that is part of the hematopoietic family. Unlike other members of this cytokine family (namely interleukin 3 and GM-CSF), this glycoprotein in its active form is a homodimer. Interleukin-5 has long been associated with the cause of several allergic diseases including allergic rhinitis and asthma, wherein a large increase in the number of circulating, airway tissue, and induced sputum eosinophils have been observed. Given the high concordance of eosinophils and, in particular, allergic asthma pathology, it has been widely speculated that eosinophils have an important role in the pathology of this disease. Drugs that target IL-5 are mepolizumab and reslizumab.
IL-5 Synonyms
IL-5,TRF,IL5,Interleukin-5
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Recombinant anti-IL-5 humanized monoclonal antibody (Shanghai CP Guojian) | 610; SSGJ-610 | Phase 3 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Asthma; Autoimmune Diseases | Details |
| SHR-1703 | SHR-1703 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Asthma; Eosinophilic Asthma; Eosinophilic Granulomatosis With Polyangiitis | Details |
| RC-1416 | RC14/16; RC-1416 | Phase 2 Clinical | Nanjing RegeneCore Biotech Co Ltd | Asthma; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive | Details |
| long-acting anti-IL-5 mAb (GSK) | Phase 1 Clinical | Glaxosmithkline Plc | Asthma | Details | |
| Mepolizumab biosimilar(Bio Thera Solutions) | BAT2606; BAT-2606 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Asthma; Autoimmune Diseases; Nasal Polyps; Sinusitis | Details |
| Mepolizumab biosimilar (CTTQ Pharma) | TQC-3566; TQC3566 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Asthma; Eosinophilic Granuloma; Eosinophilic Granulomatosis With Polyangiitis; Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Lymphohistiocytosis, Hemophagocytic; Nasal Polyps; Sinusitis; Vasculitis | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Reslizumab | CEP-38072; SCH-5570; TRFK-5; SCH-55700; CDP-835; CTx-55700 | Approved | Teva Pharmaceutical Industries Ltd | Cinquil, Cinqair, Cinqaero | United States | Asthma | Teva Respiratory Llc | 2016-03-23 | Asthma; Bronchitis; Eosinophilic Esophagitis; Hypereosinophilic Syndrome; Loiasis; Pulmonary Eosinophilia | Details |
| Depemokimab | GSK-3511294; AQ82742999; GSK3511294; GSK-294; GSK294 | Approved | Glaxosmithkline Plc | 易适来, Exdensur | United Kingdom | Asthma; Sinusitis; Nasal Polyps | Glaxosmithkline Plc | 2025-12-15 | Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Eosinophilic Asthma; Eosinophilic Granuloma; Eosinophilic Granulomatosis With Polyangiitis; Hypereosinophilic Syndrome; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis; Vasculitis | Details |
| Mepolizumab | SB-240563; 240563 | Approved | Glaxosmithkline Plc | Bosatria, Nucala, 美泊利珠单抗, 新可来 | United States | Asthma | Glaxosmithkline Llc | 2015-11-04 | Angioedema; Asthma; Bronchitis; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Eosinophilia; Eosinophilic Esophagitis; Eosinophilic Granulomatosis With Polyangiitis; Fasciitis; Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis; Virus Diseases | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to: